pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
467
stories
Aug 5, 26
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Aug 5, 26
Fecal transplant increases tolerance to peanuts sixfold in small food allergy trial
fiercebiotech
Aug 5, 26
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
Aug 5, 26
5 NextGen winners who went public this year (and which ones are hiring)
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 4, 26
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
Aug 4, 26
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 3, 26
Supernus, Indivior merge to beef up brain drug portfolio
biopharma dive
Aug 3, 26
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
Aug 3, 26
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
Jul 31, 26
Resilience and Lilly invest $750M to boost Cincinnati drug production
biopharma dive
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 31, 26
Syphilis spreads while researchers contend with federal constraints and a drug shortage
stat
Jul 31, 26
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
Jul 30, 26
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
Jul 30, 26
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 30, 26
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
stat
Jul 30, 26
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 29, 26
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
← prev
page 8 of 16
next →
